Skip to main content
Fig. 2 | BMC Proceedings

Fig. 2

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

Fig. 2

Algorithm for using the CNIC-polypill in hypertensive patients at very high risk of cardiovascular disease. AAS, acetylsalicylic acid; ATOR, atorvastatin; BP, blood pressure; CCB, calcium channel blocker; diuretic: hydrochlorothiazide, chlortalidone or indapamide; PCSK9i, proprotein convertase subtilisin-kexin type 9 inhibitor; RAM, ramipril. *Twenty or 40 mg of atorvastatin based on initial and target LDL-cholesterol. If the target is not achieved, ezetimibe/PCSK9i can be added. **Diuretic or CCB depending on patient’s metabolic profile. †Low-dose: half standard dose. §In patients with heart failure with reduced ejection fraction (HFrEF), the priority is to add spironolactone before using high doses of CCBs. Source: Coca J Hypertens. 2020;38(10):1890–98 [11]. Reproduced with permission

Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us